Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012, 156(2):151-158 | DOI: 10.5507/bp.2012.051

Apolipoprotein E polymorphism is associated with both number of diseased vessels and extent of coronary artery disease in Czech patients with CAD

Jan Machala, Anna Vaskua, Ota Hlinomazb, Petra Linhartovaa, Ladislav Grochb, Jiri Vitovecb
a Department of Pathophysiology, Faculty of Medicine, Masaryk University Brno, Czech Republic
b 1st Department of Internal Medicine and Cardioangiology, International Clinical Research Center - ICRC, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno

Aims: The impact of ApoE polymorphism on angiographic parameters was assessed in patients referred for coronary angiography.

Methods: Elective coronary angiography was performed in 671 subjects (525 men, 146 women, mean age 60±10 years) with symptoms of ischemic heart disease. The patients were divided into: no CAD group (smooth coronary vessels, n=83), one-vessel (n=155), two-vessel (n=170) and three-vessel disease (n=196). Patients with stenoses 0-50% were excluded. Within patients with CAD, we evaluated overall extent of CAD measured by the number of stenotic segments according to AHA (1 segment vs. 2-3 vs. ≥4), and the severity of the most serious stenosis (in percent). ApoE genotype was determined using real-time PCR.

Results: The frequency of ε2/ε3 genotype (n=56) was lower in the three-vessel disease group compared to one-vessel disease (OR=0.25, P=0.0019), two-vessel disease (OR=0.31, P=0.0114) or no CAD group (OR=0.24, P=0.0057). Frequency of ε2/ε3 decreased with the number of affected segments (1 vs. ≥4: OR=0.35, P=0.0143). The ε3/ε4+ε4/ε4 genotypes (n=123) were more frequent in CAD patients altogether compared with no CAD group (OR=2.30, P=0.019), while no impact of the ε4 allele on angiographic parameters within the CAD patients was detected. In ε2/ε3 carriers with CAD, lower LDL-cholesterol, total cholesterol and lower use of lipid-lowering drugs were observed.

Conclusions: The results show predominantly focal form of CAD in patients with ε2/ε3 genotype. Lower LDL-cholesterol and total cholesterol may play the key role, although other contributing factors are discussed.

Keywords: coronary artery disease, apolipoprotein E, coronary angiography, atherosclerosis, lipid-lowering treatment

Received: September 6, 2011; Accepted: April 25, 2012; Published: June 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Machal, J., Vasku, A., Hlinomaz, O., Linhartova, P., Groch, L., & Vitovec, J. (2012). Apolipoprotein E polymorphism is associated with both number of diseased vessels and extent of coronary artery disease in Czech patients with CAD. Biomedical papers, 156(2), 151-158. doi: 10.5507/bp.2012.051
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. CZSO. Cze ch Statistical Office - Deaths: by causes of death, sex and age. Available 16/05/2011 on URL: http://www.czso.cz/ csu/2010edicniplan.nsf/t/BC0030BE81/$File/401910rg02.pdf2009
    2. Boyles JK , Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985;76(4):1501-13. doi:10.1172/JCI112130 Go to original source... Go to PubMed...
    3. Innerarit y TL, Pitas RE, Mahley RW. Receptor binding of cholesterolinduced high-density lipoproteins containing predominantly apoprotein E to cultured fibroblasts with mutations at the low-density lipoprotein receptor locus. Biochemistry 1980;19(18):4359-65. Go to original source... Go to PubMed...
    4. Mahley RW , Hui DY, Innerarity TL, Weisgraber KH. Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B,E and apo-E receptors. J Clin Invest 1981;68(5):1197-206. Go to original source... Go to PubMed...
    5. Schneider WJ, Kovanen PT, Brown MS. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J Clin Invest 1981;68(4):1075- 85. Go to original source... Go to PubMed...
    6. Kolovou G D, Anagnostopoulou KK. Apolipoprotein E polymorphism, age and coronary heart disease. Ageing Res Rev 2007;6(2):94-108. doi:10.1016/j.arr.2006.11.001 Go to original source... Go to PubMed...
    7. Basu SK, Brown MS, Ho YK, Havel RJ, Goldstein JL. Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. Proc Natl Acad Sci U S A 1981;78(12):7545-9. Go to original source... Go to PubMed...
    8. Basu SK, Ho YK, Brown MS, Bilheimer DW, Anderson RG, Goldstein JL. Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem 1982;257(16):9788-95. Go to original source...
    9. Tsukamoto K, Tangirala RK, Chun S, Usher D, Puré E, Rader DJ. Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. Mol Ther 2000;1(2):189-94. doi:10.1006/mthe.2000.0028 Go to original source... Go to PubMed...
    10. Tangiral a RK, Praticó D, FitzGerald GA. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 2001;276(1):261-6. doi:10.1074/jbc.M003324200 Go to original source... Go to PubMed...
    11. Raffai R L, Loeb SM, Weisgraber KH. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2005;25(2):436-41. doi:10.1161/01.ATV.0000152613.83243.12 Go to original source... Go to PubMed...
    12. Sacre SM , Stannard AK, Owen JS. Apolipoprotein E (apoE) isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett 2003;540(1-3):181-7. doi: 10.1016/S001 4-5793(03)00261-8 Go to original source... Go to PubMed...
    13. Ali K, Middleton M, Puré E, Rader DJ. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 2005;97(9):922-7. doi:10.1161/01.RES.0000187467.67684.43 Go to original source... Go to PubMed...
    14. Baitsch D, Bock HH, Engel T. Apolipoprotein e induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol 2011;31(5):1160-8. doi:10.1161/ATVBAHA.111.222745 Go to original source... Go to PubMed...
    15. Weisgrab er KH, Rall SC, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256(17):9077-83. Go to original source...
    16. Rall SC, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982;257(8):4171-8. Go to original source...
    17. Calero O , Hortigüela R, Bullido MJ, Calero M. Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan and FRET assays. J Neurosci Methods 2009;183(2):238-40. doi:10.1016/j.jneumeth.2009.06.033 Go to original source... Go to PubMed...
    18. Mahley R W, Huang Y, Rall SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999;40(11):1933-49. Go to original source...
    19. Mamotte CD, Burke V, Taylor RR, van Bockxmeer FM. Evidence of reduced coronary artery disease risk for apolipoprotein epsilon2/3 heterozygotes. Eur J Intern Med 2002;13(4):250-5. doi: 10.1016/ S09 53-6205(02)00030-4 Go to original source... Go to PubMed...
    20. Cumming AM, Robertson FW. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet 1984;25(4):310- 3. Go to original source... Go to PubMed...
    21. Corbo RM , Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Ann Hum Genet 1999;63(Pt 4):301-10. Go to original source... Go to PubMed...
    22. Mahley R W, Rall SC. Is epsilon4 the ancestral human apoE allele? Neurobiol Aging 1999;20(4):429-30. doi: 10.1016/S019 7- 4580(99)00081-0 Go to original source... Go to PubMed...
    23. Kuusi T, Nieminen MS, Ehnholm C. Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis 1989;9(2):237-41. Go to original source... Go to PubMed...
    24. Wilson P W, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16(10):1250-5. Go to original source... Go to PubMed...
    25. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141(2):137-47. Go to original source... Go to PubMed...
    26. Eto M, Watanabe K, Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet 1986;29(6):477-84. Go to original source... Go to PubMed...
    27. Bennet A M, Di Angelantonio E, Ye Z. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298(11):1300-11. doi:10.1001/jama.298.11.1300 Go to original source... Go to PubMed...
    28. Grammer TB, Hoffmann MM, Renner W. Apolipoprotein E genotypes, circulating C-reactive protein and angiographic coronary artery disease: The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 2011;215(2):487-93. doi: 10.1016/j.atherosclerosis. 2011.01.005 Go to original source... Go to PubMed...
    29. Sudlow C , Martínez González NA, Kim J, Clark C. Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17,965 controls. Stroke 2006;37(2):364-70. doi:10.1161/01. STR.0000199065.12908.62 Go to original source... Go to PubMed...
    30. Ward H, Mitrou PN, Bowman R. APOE genotype, lipids, and coronary heart disease risk: a prospective population study. Arch Intern Med 2009;169(15):1424-9. doi:10.1001/archinternmed.2009.234 Go to original source... Go to PubMed...
    31. Mahley R W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240(4852):622-30. Go to original source... Go to PubMed...
    32. Brewer H B, Zech LA, Gregg RE, Schwartz D, Schaefer EJ. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 1983;98(5 Pt 1):623-40. Go to original source... Go to PubMed...
    33. Utermann G, Jaeschke M, Menzel J. Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett 1975;56(2):352-355. doi:10.1016/0014-5793(75)81125-2 Go to original source... Go to PubMed...
    34. de Beer F, Stalenhoef AF, Hoogerbrugge N. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol 2002;22(2):294-9. Go to original source... Go to PubMed...
    35. Menzel H J, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 1983;3(4):310-5. Go to original source... Go to PubMed...
    36. Wang XL, McCredie RM, Wilcken DE. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol 1995;15(8):1030-4. Go to original source... Go to PubMed...
    37. Li SS, Y ang J, Li LS, Wang HC. Apolipoprotein E polymorphism and the characteristics of diseased vessels in male Chinese patients with angiographic coronary artery disease: a case-case study. Clin Cardiol 2010;33(6):E30-4. doi:10.1002/clc.20703 Go to original source... Go to PubMed...
    38. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation 1985;71(5):881-8. Go to original source... Go to PubMed...
    39. Benes P, Muzik J, Benedik J. Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male Caucasians. Molecular Genetics and Metabolism 2000:137-43. Go to original source... Go to PubMed...
    40. Ilveskos ki E, Perola M, Lehtimäki T. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999;100(6):608- 13. Go to original source... Go to PubMed...
    41. Heide S, Manfred K, Gläser C, Schulz S. Apolipoprotein E (apoE) polymorphism: a risk factor for fatal coronary sclerosis? Forensic Sci Int 2009;192(1-3):62-6. doi:10.1016/j.forsciint.2009.07.020 Go to original source... Go to PubMed...
    42. Lima LM, Carvalho MG, Ferreira CN. Atheromatosis extent in coronary artery disease is not correlated with apolipoprotein-E polymorphism and its plasma levels, but associated with cognitive decline. Curr Alzheimer Res 2010;7(6):556-63. Go to original source... Go to PubMed...
    43. Jofre- Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res 2008;52(1):131-45. doi:10.1002/mnfr.200700322 Go to original source... Go to PubMed...
    44. Golledge J, Biros E, Cooper M, Warrington N, Palmer LJ, Norman PE. Apolipoprotein E genotype is associated with serum C-reactive protein but not abdominal aortic aneurysm. Atherosclerosis 2010;209(2):487-91. doi:10.1016/j.atherosclerosis.2009.09.027 Go to original source... Go to PubMed...
    45. Casas JP , Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta- analysis of 26 studies involving 23028 subjects. Circulation 2004;109(11):1359-65. doi:10.1161/01.CIR.0000121357.76910.A3 Go to original source... Go to PubMed...
    46. Kincl V, Vasku A, Meluzin J, Panovsky R, Semenka J, Groch L. Association of the eNOS 4a/b and -786T/C polymormphisms with coronary artery disease, obesity and diabetes mellitus. Folia Biol (Praha) 2009;55(5):187-91. Go to original source... Go to PubMed...
    47. Davies N M, Windmeijer F, Martin RM. Use of genotype frequencies in medicated groups to investigate prescribing practice: APOE and statins as a proof of principle. Clin Chem 2011;57(3):502-10. doi: 10.1373/clinchem.2010.156356 Go to original source... Go to PubMed...
    48. Christid is DS, Liberopoulos EN, Kakafika AI. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther 2006;11(3):211-21. doi:10.1177/1074248406293732 Go to original source... Go to PubMed...
    49. Mega JL, Morrow DA, Brown A, Cannon CP, Sabatine MS. Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29(9):1310-15. doi:10.1161/ATVBAHA.109.188474 Go to original source... Go to PubMed...
    50. Maitland -van der Zee AH, Jukema JW, Zwinderman AH. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol 2006;61(3):327- 31. Go to original source... Go to PubMed...
    51. Ballanty ne CM, Herd JA, Stein EA. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000;36(5):1572-8. Go to original source... Go to PubMed...
    52. Balcerzyk A, Zak I, Krauze J. Synergistic effects of apolipoprotein E gene epsilon polymorphism and some conventional risk factors on premature ischaemic heart disease development. Kardiol Pol 2007;65(9):1058-65; discussion 1066-57.
    53. Kawakam i K, Okumura K, Matsui H. The apolipoprotein E genotype influences the risk for vasospastic angina. Canadian Journal of Cardiology 2001:660-6.
    54. Tuzcu E, Kapadia S, Tutar E. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults - Evidence from intravascular ultrasound. Circulation 2001:2705-10. Go to original source... Go to PubMed...
    55. Loecker T, Schwartz R, Cotta C, Hickman J. Fluoroscopic coronaryartery calcification and associated coronary-disease in asymptomatic young men. J Am Coll Cardiol 1992:1167-72. Go to original source... Go to PubMed...

    Return to the content